Restricted accessResearch articleFirst published online 2020-06
Distribution of CRISPR-Cas Systems in Clinical Carbapenem-Resistant Klebsiella pneumoniae Strains in a Chinese Tertiary Hospital and Its Potential Relationship with Virulence
In this study, we aimed to characterize the CRISPR-Cas systems in clinical carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates and to investigate the potential association of CRISPR-Cas systems with bacterial virulence.
Methods:
A total of 168 CRKP strains were collected from inpatients in a teaching hospital in Jiangxi Province. Five common carbapenemase genes, subtype genes of the CRISPR-Cas system, and 13 virulence genes were amplified by PCR using specific primers. The potential virulence of all the clinical CRKP strains was tested in a Galleria mellonella infection model.
Results:
PCR analysis of five common carbapenemase genes revealed the frequency of carbapenemase gene KPC-2 was the highest in the CRISPR-negative strains, compared to CRISPR type I-E* strains or CRISPR type I-E strains (p < 0.01). Isolates having the subtype I-E* CRISPR-Cas system tended to have more virulence genes such as magA, kfu, wcaG, and allS, compared to CRISPR-negative isolates and type I-E CRISPR-Cas isolates (p < 0.01). The average survival time of the larvae infected with the isolates having the subtype I-E* CRISPR-Cas system was significantly shorter than the other two group isolates (p < 0.05).
Conclusion:
The CRKP strains, which had the subtype I-E CRISPR-Cas system or the subtype I-E* CRISPR-Cas system, showed reduced acquisition of carbapenemase genes compared to CRISPR-negative isolates. Importantly, we first found that a small portion of “CR-hvKP” strains were selected from the CRKP clones, which had the type I-E* CRISPR-Cas systems.
Get full access to this article
View all access options for this article.
References
1.
IshinoY., ShinagawaH., MakinoK., AmemuraM., and NakataA.. 1987. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169:5429–5433.
2.
BarrangouR., and HorvathP.. 2012. CRISPR: new horizons in phage resistance and strain identification. Annu. Rev. Food Sci. Technol. 3:143–162.
3.
MakarovaK.S., WolfY.I., AlkhnbashiO.S., CostaF., ShahS.A., SaundersS.J., BarrangouR., BrounsS.J., CharpentierE., HaftD.H., et al.2015. An updated evolutionary classification of CRISPR-Cas systems. Nat. Rev. Microbiol. 13:722–736.
4.
BarrangouR.2015. Diversity of CRISPR-Cas immune systems and molecular machines. Genome Biol. 16:247.
5.
GarneauJ.E., DupuisM., VillionM., RomeroD.A., BarrangouR., BoyavalP., FremauxC., HorvathP., MagadánA.H., and MoineauS.. 2010. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature, 468:67–71.
6.
MarraffiniL.A., and SontheimerE.J.. 2008. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science, 322:1843–1845.
7.
BikardD., Hatoum-AslanA., MucidaD., and MarraffiniL.A.. 2012. CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe. 12:177–186.
8.
Gomez-SimmondsA., and UhlemannA.C.. 2017. Clinical implications of genomic adaptation and evolution of carbapenem-resistant Klebsiella pneumoniae. J. Infect Dis. 215:S18–S27.
9.
LiH.Y., KaoC.Y., LinW.H., ZhengP.X., YanJ.J., WangM.C., TengC.H., TsengC.C., and WuJ.J.. 2018. Characterization of CRISPR-Cas systems in clinical. Front. Microbiol. 9:1595.
10.
HumphriesR.M., AmblerJ., MitchellS.L., CastanheiraM., DingleT., HindlerJ.A., KoethL., SeiK., TestingC.M.D., and S.W.G.o.t.S.o.SusceptibilityA. 2018. CLSI Methods Development and Standardization Working Group best practices for evaluation of antimicrobial susceptibility tests. J. Clin. Microbiol. 56:e01934-17.
11.
LiuY., WanL.G., DengQ., CaoX.W., YuY., and XuQ.F.. 2015. First description of NDM-1-, KPC-2-, VIM-2- and IMP-4-producing Klebsiella pneumoniae strains in a single Chinese teaching hospital. Epidemiol. Infect. 143:376–384.
12.
LinT.L., PanY.J., HsiehP.F., HsuC.R., WuM.C., and WangJ.T.. 2016. Imipenem represses CRISPR-Cas interference of DNA acquisition through H-NS stimulation in Klebsiella pneumoniae. Sci. Rep. 6:31644.
13.
FangC.T., ChuangY.P., ShunC.T., ChangS.C., and WangJ.T.. 2004. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J. Exp. Med. 199:697–705.
14.
YuW.L., KoW.C., ChengK.C., LeeH.C., KeD.S., LeeC.C., FungC.P., and ChuangY.C.. 2006. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin. Infect. Dis. 42:1351–1358.
15.
CompainF., BabosanA., BrisseS., GenelN., AudoJ., AilloudF., Kassis-ChikhaniN., ArletG., and DecréD.. 2014. Multiplex PCR for detection of seven virulence factors and K1/K2 capsular serotypes of Klebsiella pneumoniae. J. Clin. Microbiol. 52:4377–4380.
16.
YuW.L., KoW.C., ChengK.C., LeeC.C., LaiC.C., and ChuangY.C.. 2008. Comparison of prevalence of virulence factors for Klebsiella pneumoniae liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes. Diagn. Microbiol. Infect. Dis. 62:1–6.
17.
El Fertas-AissaniR., MessaiY., AlouacheS., and BakourR.. 2013. Virulence profiles and antibiotic susceptibility patterns of Klebsiella pneumoniae strains isolated from different clinical specimens. Pathol. Biol. (Paris), 61:209–216.
18.
TurtonJ.F., PerryC., ElgohariS., and HamptonC.V.. 2010. PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. J. Med. Microbiol. 59:541–547.
19.
McLaughlinM.M., AdvinculaM.R., MalczynskiM., BarajasG., QiC., and ScheetzM.H.. 2014. Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes. BMC Infect. Dis. 14:31.
20.
LiQ., XieX., YinK., TangY., ZhouX., ChenY., XiaJ., HuY., IngmerH., LiY, et al.2016. Characterization of CRISPR-Cas system in clinical Staphylococcus epidermidis strains revealed its potential association with bacterial infection sites. Microbiol. Res. 193:103–110.
21.
ShenJ., ZhouJ., XuY., and XiuZ.. 2019. Prophages contribute to genome plasticity of Klebsiella pneumoniae and may involve the chromosomal integration of ARGs in CG258. Genomics [Epub ahead of print]; doi:10.1016/j.ygeno.2019.06.016.
22.
AydinS., PersonneY., NewireE., LaverickR., RussellO., RobertsA.P., and EnneV.I.. 2017. Presence of Type I-F CRISPR/Cas systems is associated with antimicrobial susceptibility in Escherichia coli. J. Antimicrob. Chemother. 72:2213–2218.
23.
ShabbirM.A., WuQ., ShabbirM.Z., SajidA., AhmedS., SattarA., TangY., LiJ., MaanM.K., HaoH, et al.2018. The CRISPR-cas system promotes antimicrobial resistance in Campylobacter jejuni. Future Microbiol. 13:1757–1774.
24.
HuangW., WangG., SebraR., ZhugeJ., YinC., Aguero-RosenfeldM.E., SchuetzA.N., DimitrovaN., and FallonJ.T.. 2017. Emergence and evolution of multidrug-resistant Klebsiella pneumoniae with both. Antimicrob. Agents Chemother. 61:e00076-17.
25.
ShenJ., LvL., WangX., XiuZ., and ChenG.. 2017. Comparative analysis of CRISPR-Cas systems in Klebsiella genomes. J. Basic Microbiol. 57:325–336.
26.
PawlukA., DavidsonA.R., and MaxwellK.L.. 2018. Anti-CRISPR: discovery, mechanism and function. Nat. Rev. Microbiol. 16:12–17.
27.
Hatoum-AslanA., and MarraffiniL.A.. 2014. Impact of CRISPR immunity on the emergence and virulence of bacterial pathogens. Curr. Opin. Microbiol. 17:82–90.
28.
FuQ., SuZ., ChengY., WangZ., LiS., WangH., SunJ., and YanY.. 2017. Clustered, regularly interspaced short palindromic repeat (CRISPR) diversity and virulence factor distribution in avian Escherichia coli. Res. Microbiol. 168:147–156.
29.
WiedenheftB., and Bondy-DenomyJ.. 2017. CRISPR control of virulence in Pseudomonas aeruginosa. Cell Res. 27:163–164.
30.
LiR., FangL., TanS., YuM., LiX., HeS., WeiY., LiG., JiangJ., and WuM.. 2016. Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity. Cell Res. 26:1273–1287.
31.
SiuL.K., YehK.M., LinJ.C., FungC.P., and ChangF.Y.. 2012. Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect. Dis. 12:881–887.
32.
YaoB., XiaoX., WangF., ZhouL., ZhangX., and ZhangJ.. 2015. Clinical and molecular characteristics of multi-clone carbapenem-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in a tertiary hospital in Beijing, China. Int. J. Infect. Dis. 37:107–112.
33.
YehK.M., KurupA., SiuL.K., KohY.L., FungC.P., LinJ.C., ChenT.L., ChangF.Y., and KohT.H.. 2007. Capsular serotype K1 or K2, rather than magA and rmpA, is a major virulence determinant for Klebsiella pneumoniae liver abscess in Singapore and Taiwan. J. Clin. Microbiol. 45:466–471.
34.
SiuL.K., FungC.P., ChangF.Y., LeeN., YehK.M., KohT.H., and IpM.. 2011. Molecular typing and virulence analysis of serotype K1 Klebsiella pneumoniae strains isolated from liver abscess patients and stool samples from noninfectious subjects in Hong Kong, Singapore, and Taiwan. J. Clin. Microbiol. 49:3761–3765.
35.
WyresK.L., WickR.R., JuddL.M., FroumineR., TokolyiA., GorrieC.L., LamM.M.C., DuchêneS., JenneyA., and HoltK.E.. 2019. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae. PLoS Genet. 15:e1008114.
36.
GawryszewskaI., MalinowskaK., KuchA., Chrobak-ChmielD., TrokenheimL.L., HryniewiczW., and SadowyE.. 2017. Distribution of antimicrobial resistance determinants, virulence-associated factors and clustered regularly interspaced palindromic repeats loci in isolates of Enterococcus faecalis from various settings and genetic lineages. Pathog. Dis. 75:doi:10.1093/femspd/ftx021.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
